Early identification of high-risk patients remains a critical challenge in sepsis management, and while traditional biomarkers such as procalcitonin (PCT) and C-reactive protein (CRP) are widely used, they have limited predictive value for disease progression and outcomes [34, 35]. The gene discussed is CRP; the disease is Sepsis.